Michael C. Donegan - 29 Sep 2021 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TXMD	Restricted Stock Units	Award	$0	+38,954		$0.000000	38,954	29 Sep 2021	Common Stock	38,954	$0.000000	Direct	F1, F2
transaction	TXMD	Non-Qualified Stock Option (right to buy)	Other	$0	-50,000	-100%	$0.000000^*	0	29 Sep 2021	Common Stock	50,000	$5.01	Direct	F3, F4
transaction	TXMD	Non-Qualified Stock Option (right to buy)	Other	$0	-100,000	-100%	$0.000000^*	0	29 Sep 2021	Common Stock	100,000	$8.92	Direct	F3, F5
transaction	TXMD	Non-Qualified Stock Option (right to buy)	Other	$0	-40,000	-100%	$0.000000^*	0	29 Sep 2021	Common Stock	40,000	$6.83	Direct	F3, F6
transaction	TXMD	Non-Qualified Stock Option (right to buy)	Other	$0	-100,000	-100%	$0.000000^*	0	29 Sep 2021	Common Stock	100,000	$5.16	Direct	F3, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Restricted stock units (RSUs) issued pursuant to the Issuer's stock option exchange program approved by stockholders at the Issuer's 2021 annual meeting (the "Option Exchange Program"). Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2	Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.
F3	Stock options exchanged for RSUs pursuant to the Option Exchange Program.
F4	Underlying shares were subject to vesting as follows: 12,500 shares on the first anniversary date of the grant, 12,500 shares on the second anniversary date of the grant, 12,500 shares on the third anniversary date of the grant, and 12,500 shares on the fourth anniversary date of the grant.
F5	Underlying shares were subject to vesting as follows: equal monthly installments over 12 months.
F6	Underlying shares were subject to vesting as follows: 13,333 shares on the first anniversary date of the grant, 13,333 shares on the second anniversary date of the grant, and 13,334 shares on the third anniversary date of the grant.
F7	Underlying shares were subject to vesting as follows: 33,334 shares on the first anniversary date of the grant, 33,333 shares on the second anniversary date of the grant, and 33,333 shares on the third anniversary date of the grant.